Palma de Mallorca, April 07, 2015 –

Laminar Pharma announced today that a key patent for the company, owned by the University of the Balearic Islands (UIB) and licensed in exclusive to Laminar Pharma, has been granted by the United States Patent and Trademark Office (USPTO). The patent has been published with number 9000042 and covers potential oncology indications of its lead product 2OHOA, currently being evaluated in a multicentre Phase I/IIa clinical study in patients with advanced solid tumours, including malignant glioma (MIN-001-1203).

This US patent will run until December 2029 (not including supplementary protection certificate, SPC) and provides a strong protection for Laminar Pharma’s novel lipid-modulation technology as a potential breakthrough treatment for several types of aggressive cancers that currently still have very important medical needs unmet.

The USPTO patent issue follows recent grant confirmation of the equivalent patent in Europe, Japan, China, Russia, Mexico and Spain, while other corresponding patent applications for 2OHOA in oncology are pending in other major markets globally. Laminar Pharma now owns or has exclusive rights on 5 global patent families, building a critical comprehensive and enforceable patent portfolio to protect the commercial potential of its innovative Membrane-Lipid Therapy (MLT) technology, including 2OHOA for cancer and other indications, as well as combinatory regimes of 2OHOA with other well established oncology drugs.

The next milestone in the 2OHOA program will be the initiation of a PIIb placebo controlled study of 2OHOA plus standard of care in patients with newly-diagnosed glioblastoma, which has already been discussed with the European Medicines Agency (EMA) as part of the clinical development planned to pursue the Orphan Medicinal Product designation in Europe, obtained in October 2011.